This DyLight® 594 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 594 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Red Laser (590 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this AFS98 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Reported Applications For Relevant Conjugates ?
For specific conjugates of this clone, review literature for suggested application details.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone AFS98 recognizes an epitope on mouse CD115.
CD115 is expressed on monocytes, macrophages, plasmacytoid and conventional dendritic cells, osteoclasts, and peritoneal exudate cells.
CD115 antibody, clone AFS98, recognizes CD115, also known as mouse colony-stimulating factor 1 receptor (CSF-1R and macrophage colony-stimulating factor receptor (M-CSFR). CD115 is a 150kDa single-pass type I membrane protein encoded by the c-fms gene that belongs to the type III protein tyrosine kinase receptor family. CD115 has an immunoglobulin-like extracellular domain, transmembrane domain, and C-terminal tail receptor and is expressed by monocytes, macrophages, plasmacytoid and conventional dendritic cells (DCs), osteoclasts, and their precursors. CD115 is the receptor for CSF1, also known as M-CSF, and IL-34. Binding and signaling through CD115 regulates the proliferation, differentiation, survival, and cytokine-production of monocytes and macrophages1,2. In addition, CD115 plays a key role in the differentiation and proliferation of osteoclasts as well as their bone resorption activity3. Mutations in CSF-1R are associated with cancer, including myeloid malignancies, Alzheimer’s disease, and other inflammatory and autoimmune diseases4. The presence of tumor-associated macrophages (TAMs) expressing CSF-1R correlates with poor survival in various tumor types5,6, and efforts to eliminate these TAMs using CSF1R small-molecule inhibitors and monoclonal antibodies are currently in clinical trials7.
Macrophage colony stimulating factor (M-CSF), IL-34
NCBI Gene Bank ID
References & Citations
1. Stanley ER., et al. (1982) Cell. 28:71–81
2. Roussel MF., at al. (1988) Cold Spring Harb Symp Quant Biol. 53:521–530
3. Park-Min, KH., et al. (2020) Exp Mol Med 52, 1239–1254
4. Tak, P. P., at al. (2016) Nat. Rev. Drug Disco. 16, 53–70
5. d’Amore F. (2014) Histopathology. 65:490–500
6. Wei YQ., et al. (2012) PLoS One. 7:e50946
7. Rüttinger D., et al. (2017) J Immunother Cancer. 5(1):53
Products are for research use only. Not for use in diagnostic or therapeutic procedures.